Fulcrum Therapeutics Inc.
FULC
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$0.00
▼ -100.0% YoY
Net Income (TTM)
-$76M
▼ -670.0% YoY
Op. Margin
–
ROIC
-21.09%
▼ -15.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$65M
▼ -2319.0% YoY
Op. Cash Flow (TTM)
-$65M
▼ -2608.1% YoY
Net Debt
-$110M
Net Cash Position
Cash & Equiv.
$116M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with FULC
Held by ETFs
FULC is in 15 US ETFs. The largest of them, with FULC's weight in each:
Fulcrum Therapeutics (FULC) in three numbers
Questions about Fulcrum Therapeutics
Is Fulcrum Therapeutics a high-quality business?
Fulcrum Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$110M, and its weakest is return on capital at -21.1%. The Quality tab shows every check against its target.
Does Fulcrum Therapeutics (FULC) pay a dividend?
No. Fulcrum Therapeutics (FULC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 8 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in FULC's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing FULC
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.